{
  "_note": "합성 메타데이터. 실제 임상 의사결정에 사용 금지. 출처는 학회 가이드라인 우선.",
  "drugs": [
    {
      "id": "semaglutide_2_4",
      "name": "semaglutide 2.4mg (Wegovy)",
      "class": "GLP-1 RA",
      "fda_obesity_approved": true,
      "approx_tbwl_pct": 14.9,
      "korea_approved": true,
      "key_cv_trial": "SELECT (NEJM 2023)",
      "primary_mediations": ["weight_loss", "anti_inflammatory_direct", "glucose"],
      "iis_potential_korea": "high"
    },
    {
      "id": "liraglutide_3_0",
      "name": "liraglutide 3.0mg (Saxenda)",
      "class": "GLP-1 RA",
      "fda_obesity_approved": true,
      "approx_tbwl_pct": 8.0,
      "korea_approved": true,
      "key_cv_trial": "LEADER (T2DM cohort)",
      "primary_mediations": ["weight_loss", "glucose"],
      "iis_potential_korea": "moderate"
    },
    {
      "id": "tirzepatide",
      "name": "tirzepatide (Zepbound/Mounjaro)",
      "class": "GIP/GLP-1 dual",
      "fda_obesity_approved": true,
      "approx_tbwl_pct": 22.5,
      "korea_approved": true,
      "key_cv_trial": "SURPASS-CVOT, SUMMIT (HFpEF)",
      "primary_mediations": ["weight_loss", "glucose", "natriuresis"],
      "iis_potential_korea": "high"
    },
    {
      "id": "retatrutide",
      "name": "retatrutide (LY3437943)",
      "class": "GIP/GLP-1/GCG triple",
      "fda_obesity_approved": false,
      "approx_tbwl_pct": 24.2,
      "korea_approved": false,
      "key_cv_trial": "TRIUMPH program",
      "primary_mediations": ["weight_loss", "glucose", "anti_inflammatory_direct"],
      "iis_potential_korea": "low"
    },
    {
      "id": "cagrisema",
      "name": "CagriSema (cagrilintide+semaglutide)",
      "class": "Amylin+GLP-1",
      "fda_obesity_approved": false,
      "approx_tbwl_pct": 22.7,
      "korea_approved": false,
      "key_cv_trial": "REDEFINE program",
      "primary_mediations": ["weight_loss", "autonomic", "glucose"],
      "iis_potential_korea": "low"
    },
    {
      "id": "orforglipron",
      "name": "orforglipron (oral GLP-1)",
      "class": "Oral non-peptide GLP-1 RA",
      "fda_obesity_approved": false,
      "approx_tbwl_pct": 14.7,
      "korea_approved": false,
      "key_cv_trial": "ATTAIN program",
      "primary_mediations": ["weight_loss", "glucose"],
      "iis_potential_korea": "moderate"
    },
    {
      "id": "maritide",
      "name": "MariTide (maridebart cafraglutide)",
      "class": "GIPR antagonist + GLP-1 RA",
      "fda_obesity_approved": false,
      "approx_tbwl_pct": 20.0,
      "korea_approved": false,
      "key_cv_trial": "MARITIME program",
      "primary_mediations": ["weight_loss", "anti_inflammatory_direct"],
      "iis_potential_korea": "low"
    },
    {
      "id": "setmelanotide",
      "name": "setmelanotide (Imcivree)",
      "class": "MC4R agonist",
      "fda_obesity_approved": true,
      "approx_tbwl_pct": 11.0,
      "korea_approved": false,
      "key_cv_trial": "rare-disease focus, no large CVOT",
      "primary_mediations": ["weight_loss", "autonomic"],
      "iis_potential_korea": "low"
    },
    {
      "id": "pioglitazone",
      "name": "pioglitazone",
      "class": "TZD (PPAR-gamma)",
      "fda_obesity_approved": false,
      "approx_tbwl_pct": -2.0,
      "korea_approved": true,
      "key_cv_trial": "PROactive, IRIS",
      "primary_mediations": ["anti_inflammatory_direct", "glucose"],
      "iis_potential_korea": "moderate"
    }
  ]
}